Further studies of XAF1 and other potential candidates associated with our adaptive resistance evolution signature will undoubtedly provide new avenues for therapeutic synergies with TMZ especially for MGMT-hypermethylated GBM. The gene discussed is MGMT; the disease is glioblastoma.